Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 15/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352625 | 0.89 | HPGDS (0.80) | HPGDS | |
| SCHEMBL20799517 | 0.85 | ALDH1A1 (0.62) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL1350785 | 0.85 | NPC1 (0.66) | HPGDSALDH1A1HDAC6HDAC3HDAC1 | |
| SCHEMBL4407431 | 0.84 | ALDH1A1 (0.68) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL61795 | 0.84 | ALDH1A1 (0.64) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL3845152 | 0.82 | HPGDS (0.78) | HPGDSALDH1A1F2GLAHPGD | |
| Hydrochloric Acid SCHEMBL6085328 | 0.82 | ALDH1A1 (0.62) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL1353774 | 0.82 | HDAC8 (0.57) | HPGDSHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL1352478 | 0.81 | HDAC3 (0.46) | HPGDSHDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL1352582 | 0.81 | KDR (0.46) | HPGDSHDAC6HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | claimed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011146591-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | HPGDS 1550/4885ALDH1A1 487/4885F2 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.